LXR Biotechnology Inc. is a biopharmaceutical company engaged in the research and development of therapeutics to treat diseases caused by or associated with apoptosis. Apoptosis is a form of programmed cell death that occurs as part of the natural development and maintenance of healthy tissues and organs. The Company implemented a strategic plan to direct its resources primarily toward developing Elirex(TM) and finding a corporate partner for the further development and commercialization of CP-Cardiosol(TM) and HK-Cardiosol(TM). LXR also allocated limited resources for the further development of SARPs and Lexirin(TM), while focusing less on Bak, Fas((DELTA))(TM) and Urine DNA Analysis. In addition, the Company decided in 1998 not to continue with the Scanning Laser Digital Imaging Technology (SLDI) and recently decided to discontinue the Maspin project as well.
(Source: 10-K) – less–ZoomInfo